Premnath V | Drugs Monitor

(30 Jan 2021) Tocilizumab- study supports the use of tocilizumab in COVID-19 ARDS patients

February 1, 2021

Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale https://doi.org/10.7759/cureus.12290 An observational study was conducted from Feb 2020 to May 2020 on COVID-19 ARDS patients with hyperinflammation. A total of 244 patients with COVID-19 were… Continue reading "(30 Jan 2021) Tocilizumab- study supports the use of tocilizumab in COVID-19 ARDS patients"

(29 Jan 2021) Corticosteroids- showed a statistically significant decrease in mortality

February 1, 2021

High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response https://doi.org/10.1371/journal.pone.0243964 HDCPT showed a statistically significant decrease in mortality (HR = 0.087 [95% CI 0.021-0.36]; P < 0.001). 30-day time course analysis of laboratory… Continue reading "(29 Jan 2021) Corticosteroids- showed a statistically significant decrease in mortality"

(28 Jan 2021) Tocilizumab- incidence of secondary nosocomial infections was high

February 1, 2021

Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain https://doi.org/10.1080/17512433.2021.1875819 162 patients (median age 64 years; 70.4% male) were included in a retrospective cohort in Spain. At time of TCZ administration, 48.1%… Continue reading "(28 Jan 2021) Tocilizumab- incidence of secondary nosocomial infections was high"

(27 Jan 2021) Colchicine- reduces the composite rate of death or hospitalization

January 28, 2021

Efficacy of Colchicine in Non-Hospitalized Patients with COVID-19 https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1 NCT04322682- A total of 4488 patients were enrolled. The primary endpoint occurred in 4.7% of the patients in the colchicine group and 5.8% of those in the placebo group (odds ratio,… Continue reading "(27 Jan 2021) Colchicine- reduces the composite rate of death or hospitalization"

(26 Jan 2021) Favipiravir- decreases the hospital stay and the need for mechanical ventilation

January 28, 2021

Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study https://doi.org/10.1007/s00705-021-04956-9 NCT04351295-This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the… Continue reading "(26 Jan 2021) Favipiravir- decreases the hospital stay and the need for mechanical ventilation"

(26 Jan 2021) Anakinra- did not improve outcomes in patients with mild-to-moderate COVID-19 pneumonia

January 28, 2021

Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial https://doi.org/10.1016/S2213-2600(20)30556-7 NCT04341584-The study was stopped early following the recommendation of the data and safety monitoring board, after the recruitment of… Continue reading "(26 Jan 2021) Anakinra- did not improve outcomes in patients with mild-to-moderate COVID-19 pneumonia"

(25 Jan 2021) Corticosteroids- short-term early use may prolong SARS-CoV 2 shedding

January 28, 2021

Early Use of Corticosteroid May Prolong SARS-CoV-2 Shedding in Non-Intensive Care Unit Patients with COVID-19 Pneumonia: A Multicenter, Single-Blind, Randomized Control Trial https://doi.org/10.1159/000512063 NCT04273321- this trial was terminated early because the number of patients with COVID-19 pneumonia in all the… Continue reading "(25 Jan 2021) Corticosteroids- short-term early use may prolong SARS-CoV 2 shedding"

(22 Jan 2021) Bamlanivimab-associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11

January 28, 2021

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial https://doi.org/10.1001/jama.2021.0202 NCT04427501- Among the 577 patients who were randomized and received an infusion (mean age, 44.7… Continue reading "(22 Jan 2021) Bamlanivimab-associated with a statistically significant reduction in SARS-CoV-2 viral load at day 11"

(22 Jan 2021) Chloroquine- No significant differences in clinical or virological outcome with nasal drops

January 28, 2021

Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial https://doi.org/10.4103/ijmr.IJMR_3665_20 CTRI/2020/04/024729-his randomized clinical trial was done with a sample size of 60. Nasal CQN was associated with local irritation in seven and non-compliance in one of… Continue reading "(22 Jan 2021) Chloroquine- No significant differences in clinical or virological outcome with nasal drops"

(22 Jan 2021) Tocilizumab- TCZ plus SoC was not superior in improving clinical outcomes at 15 days

January 28, 2021

Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial https://doi.org/10.1001/jama.2021.0202 NCT04403685-A total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed… Continue reading "(22 Jan 2021) Tocilizumab- TCZ plus SoC was not superior in improving clinical outcomes at 15 days"

Author: Premnath V